GLP-1 Daily: Ozempic & Wegovy News
Retatrutide Black Market Hits Before Approval; Wegovy Pill Generics Far Off
Tuesday, October 13, 2026 · 6 min
Eli Lilly is moving against med spas and online sellers marketing its unapproved obesity drug retatrutide, which is still in phase 3. Separately, patent and bioequivalence hurdles suggest a generic Wegovy pill could be more than a decade away.
Listen
Show notes
Eli Lilly is moving against med spas and online sellers marketing its unapproved obesity drug retatrutide, which is still in phase 3. Separately, patent and bioequivalence hurdles suggest a generic Wegovy pill could be more than a decade away.
In this episode
- Lilly is fighting a black market for its new obesity drug even before it launches | PharmaVoice — PharmaVoice
“Eli Lilly is no stranger to competition from compounded versions of its tirzepatide GLP-1 diabetes and weight loss drugs. But the problem recently took a turn into uncharted territory when medical spas, online sellers and other businesses began marketing products purporting to…”
- Wegovy Pill: Sales, Patents, Generic Hurdles – INTO BIOTECH — INTO BIOTECH
“Novo Nordisk’s (NVO) oral obesity drug, the Wegovy pill (oral semaglutide 25 mg), passed DKK 3.2 billion in quarterly sales just two quarters after its U.S. launch. Yet even once its patents start to expire, this pill will be far harder to copy than the injection.”
- GLP-1 Benefits Beyond Weight Loss: 2026 Evidence Scorecard — Inside Peptides
“GLP-1 medicines now have FDA-approved uses well beyond weight loss and blood sugar: lowering heart-attack and stroke risk, slowing kidney disease in type 2 diabetes, treating a serious form of fatty liver disease, and treating obstructive sleep apnea. But not every hopeful…”